Proactive Investors - Run By Investors For Investors

Luminex shares plummet on 4Q earnings miss, says 2019 will be year of transition

Quarterly consolidated revenue climbed 4% to $81.1 million, beating the Wall Street consensus
A scientist looking through a microscope
The biotech recently closed the acquisition of EMD Millipore

Luminex Corp (NASDAQ:LMNX) shares were down sharply after reporting fourth-quarter earnings that missed analysts estimates and saying it expected 2019 to be a transitional year.

For the fourth quarter, the biotech company posted net income of $1.7 million, or $0.04 per diluted share, compared with the $0.09 average forecast of analysts. Fourth-quarter consolidated revenue climbed 4% to $81.1 million, beating the $79.43 million consensus.

The stock declined 4.8% to $26.80 in Monday’s after-market but picked up momentum, falling nearly 11% Tuesday Morning.

READ: HekaBio CEO says Orgenesis taken 'great steps' to solve biotech manufacturing cost problem

On December 31, the Austin, Texas-based company closed the acquisition of EMD Millipore Corp's flow cytometry portfolio for $69.9 million in cash, plus about $5.1 million in committed inventory purchases. Earlier last year, the company reported the departure of LabCorp as a customer.

"We expect 2019 to be a transitional year while we further adjust to the departure of LabCorp and the inclusion of Millipore's flow cytometry business," CEO Nachum "Homi" Shamir said in a statement.

Contact Dennis Fitzgerald at [email protected]

 

View full LMNX profile View Profile

Luminex Corporation Timeline

Related Articles

pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
Social media use
Thu
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use